恆富控股(00643.HK):50.28%股權易手馬小秋致提全面要約 明日復牌
格隆匯10月2日丨恆富控股(00643.HK)公佈,於2022年9月30日,賣方李海楓及Dragon Peace Limited擬向買方建泉融資出售公司合計50.28%股份,總現金代價為9829.82萬港元。於完成後,買方作為要約人按例須作出強制性無條件現金要約。每股要約價為現金0.239港元,較2022年9月29日收市價折讓約0.42%。
據悉,要約人為於英屬處女羣島註冊成立的投資控股有限公司。於聯合公佈日期,要約人由馬小秋全資實益擁有。馬小秋為要約人的唯一董事。
此外,公司已申請股份自2022年10月3日上午九時正起於聯交所復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.